DexCom (DXCM) Shares Decline, Here’s the Reason

Recent Developments

DexCom (NASDAQ:DXCM), a company specializing in medical devices, experienced a 2.6% decline in its share price during morning trading. This drop followed reductions in price targets by analysts at Piper Sandler and Bernstein, who voiced apprehensions about DexCom’s future growth and current valuation.

These analyst actions coincided with Jake Leach stepping into his new position as President and CEO. Piper Sandler lowered its price target from $100 to $75, citing a possible deceleration in growth based on DexCom’s guidance for the end of the year. Bernstein also revised its target downward, from $98 to $84, due to valuation worries. Despite these adjustments, both firms maintained their favorable outlooks on the stock. In contrast, Leerink Partners took a more optimistic stance, raising its price target from $81 to $92, referencing encouraging data related to DexCom’s G7 product.

Market reactions to news can sometimes be exaggerated, and significant price declines may offer attractive entry points for investors seeking quality stocks. Considering this, is DexCom now a good investment opportunity?

Market Perspective

DexCom’s stock has shown considerable volatility, with 15 instances of price swings exceeding 5% over the past year. Today’s decline suggests that while investors see the news as significant, it does not fundamentally alter their view of the company.

The most notable movement in the last year occurred two months ago, when DexCom’s shares plummeted by 14.8% after the company released earnings that fell short of expectations. Despite reporting a 21% year-over-year revenue increase to $1.21 billion and adjusted earnings per share of $0.61—both surpassing analyst forecasts—DexCom’s stock still dropped. The company also raised its 2025 revenue outlook to around $4.64 billion. However, the market’s reaction indicated that investors had anticipated even stronger results and a more substantial guidance boost, leading to a sell-off despite the positive numbers.

Since the start of the year, DexCom’s share price has risen by 1.8%. Nevertheless, at $67.75 per share, it remains 25.3% below its 52-week peak of $90.75, reached in February 2025. An investor who purchased $1,000 worth of DexCom stock five years ago would now see that investment valued at $698.32.

Many major companies—such as Microsoft, Alphabet, Coca-Cola, and Monster Beverage—began as lesser-known growth stories that capitalized on major trends. We have identified another promising opportunity: a profitable AI semiconductor company that has yet to gain widespread attention from Wall Street.